A patient who did not receive maintenance steroids after a first optic neuritis attack but was treated with high‑dose steroids after a second attack and responded—does she still require rituximab as a long‑term steroid‑sparing therapy?

Yes, she still needs rituximab for long-term relapse prevention despite responding to steroids after the second attack.

A patient with recurrent optic neuritis who responds to acute steroid treatment but has already experienced a second attack requires disease-modifying therapy with rituximab to prevent future relapses and permanent disability. The steroid response addresses only the acute inflammation but does not prevent subsequent attacks, which carry cumulative risk of irreversible vision loss.

Clinical Reasoning

Why Steroid Response Alone Is Insufficient

The pattern described—no maintenance therapy after the first attack, followed by a second attack requiring steroids—demonstrates active, relapsing disease. Key evidence shows:

• Recurrent optic neuritis with steroid dependence is a hallmark of MOG-associated disease (MOGAD) or neuromyelitis optica spectrum disorder (NMOSD) 1. Case vignettes specifically describe patients with "flaring up of symptoms after tapering of oral steroids" and "recurrent and steroid-dependent isolated ON" as high-risk for MOG-IgG seropositivity 1.

• Steroid responsiveness does not predict long-term stability. A 2026 case report documented a 23-year-old woman with MOGAD whose optic neuritis was "unresponsive to intravenous corticosteroids" initially, but even after achieving recovery with plasmapheresis, she experienced "a second episode...despite ongoing steroid therapy" 2. This patient required rituximab to remain relapse-free.

Evidence for Rituximab as Essential Maintenance Therapy

Rituximab is the appropriate steroid-sparing agent for recurrent optic neuritis in the context of MOGAD or NMOSD:

• In a 2017 randomized controlled trial of 68 patients with NMOSD, rituximab decreased relapse rate more than azathioprine 3.

• A 2017 six-year follow-up study of five patients with NMO/NMOSD (including one with recurrent optic neuritis) treated with rituximab showed no relapses during the treatment period while EDSS scores improved in all patients 4. The maintenance regimen involved infusions every 2 months initially, then every 6 months with CD19 B-cell monitoring.

• Multiple case reports demonstrate that rituximab prevents relapses in steroid-dependent recurrent optic neuritis. A 4-year-old with ADEM followed by recurrent ON "relapsed under treatment with azathioprine when CD19 cells reappeared" but "has not relapsed since her CD19 count was reduced and kept low with rituximab" 5.

• The FDA label for rituximab confirms its use in pemphigus vulgaris with a similar relapse-prevention paradigm: initial infusions followed by maintenance dosing at 12 and 18 months 6.

Algorithm for This Patient

1. Confirm the underlying diagnosis (if not already done):

   • Test for anti-MOG antibodies (serum, cell-based assay) 1
   • Test for anti-AQP4 antibodies if MOG-negative
   • Obtain brain and orbital MRI to assess for demyelinating lesions

2. Initiate rituximab immediately while completing the current steroid taper:

   • Standard induction: 1,000 mg IV on Day 1 and Day 15 6, 4
   • Premedicate with methylprednisolone, acetaminophen, and antihistamine 6
   • Monitor CD19 B-cell counts every 2 months 4

3. Maintenance rituximab dosing:

   • 500 mg IV every 6 months, adjusted based on CD19 counts 6, 4
   • Continue for at least 2 years, potentially longer depending on disease activity

4. Taper steroids gradually after rituximab initiation:

   • Do not abruptly discontinue, as this increases relapse risk 1
   • Target complete steroid withdrawal by 3-6 months

Critical Pitfalls to Avoid

• Do not rely on steroids alone for maintenance. The 2018 MOG encephalomyelitis guidelines explicitly list "re-occurrence of symptoms after tapering of oral steroids" as a red flag requiring MOG-IgG testing and escalation to steroid-sparing therapy 1.

• Do not delay rituximab initiation. Each relapse carries risk of permanent vision loss. A 2026 review emphasizes that "prophylactic treatment of NMOSD recurrence must be immediately performed when it is identified because the progression of disability is related to the severity of attacks" 7.

• Do not use azathioprine or mycophenolate as first-line alternatives. While these agents have some efficacy 3, rituximab demonstrates superior relapse reduction in head-to-head trials 3 and is specifically effective for antibody-mediated optic neuritis 2, 8, 5.

Monitoring and Long-Term Management

• CD19 B-cell monitoring is essential to guide maintenance dosing. Relapses correlate with CD19 cell reappearance 5, 4.

• Meningococcal prophylaxis with penicillin V is recommended during rituximab therapy 9.

• Visual function monitoring with optical coherence tomography (OCT) every 3-6 months to detect subclinical progression 2.

The evidence overwhelmingly supports that steroid responsiveness after an acute attack does not eliminate the need for disease-modifying therapy. Rituximab is the definitive treatment to prevent the third, fourth, and subsequent attacks that would otherwise occur in this relapsing disease.